Vein of Marshall Ethanol Infusion for AF Ablation; A Review
- PMID: 38673710
- PMCID: PMC11050818
- DOI: 10.3390/jcm13082438
Vein of Marshall Ethanol Infusion for AF Ablation; A Review
Abstract
The outcomes of persistent atrial fibrillation (AF) ablation are modest with various adjunctive strategies beyond pulmonary vein isolation (PVI) yielding largely disappointing results in randomised controlled trials. Linear ablation is a commonly employed adjunct strategy but is limited by difficulty in achieving durable bidirectional block, particularly at the mitral isthmus. Epicardial connections play a role in AF initiation and perpetuation. The ligament of Marshall has been implicated as a source of AF triggers and is known to harbour sympathetic and parasympathetic nerve fibres that contribute to AF perpetuation. Ethanol infusion into the Vein of Marshall, a remnant of the superior vena cava and key component of the ligament of Marshall, may eliminate these AF triggers and can facilitate the ease of obtaining durable mitral isthmus block. While early trials have demonstrated the potential of Vein of Marshall 'ethanolisation' to reduce arrhythmia recurrence after persistent AF ablation, further randomised trials are needed to fully determine the potential long-term outcome benefits afforded by this technique.
Keywords: Vein of Marshall; atrial fibrillation; ethanol infusion; mitral isthmus ablation.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Acute mitral isthmus block during catheter ablation with vein of Marshall ethanol infusion: Angiographic considerations.Arch Cardiovasc Dis. 2024 Feb;117(2):119-127. doi: 10.1016/j.acvd.2023.11.001. Epub 2023 Nov 19. Arch Cardiovasc Dis. 2024. PMID: 38040560
-
Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial.JAMA. 2020 Oct 27;324(16):1620-1628. doi: 10.1001/jama.2020.16195. JAMA. 2020. PMID: 33107945 Free PMC article. Clinical Trial.
-
Marshall bundle elimination, Pulmonary vein isolation, and Line completion for ANatomical ablation of persistent atrial fibrillation (Marshall-PLAN): Prospective, single-center study.Heart Rhythm. 2021 Apr;18(4):529-537. doi: 10.1016/j.hrthm.2020.12.023. Epub 2020 Dec 29. Heart Rhythm. 2021. PMID: 33383226
-
Ethanol Infusion of Vein of Marshall for the Treatment of Persistent Atrial Fibrillation: The Basics and Clinical Practice.J Cardiovasc Dev Dis. 2022 Aug 16;9(8):270. doi: 10.3390/jcdd9080270. J Cardiovasc Dev Dis. 2022. PMID: 36005434 Free PMC article. Review.
-
Atrial Fibrillation Ablation Using Vein of Marshall Ethanol Infusion.Methodist Debakey Cardiovasc J. 2021 Apr 5;17(1):52-55. doi: 10.14797/ZQME8581. Epub 2021 Mar 25. Methodist Debakey Cardiovasc J. 2021. PMID: 34104321 Free PMC article. Review.
Cited by
-
Combined ethanol and radiofrequency ablation for the elimination of focal atrial tachycardia originating from the Marshall bundle.Ann Med Surg (Lond). 2024 Aug 14;86(9):5648-5653. doi: 10.1097/MS9.0000000000002461. eCollection 2024 Sep. Ann Med Surg (Lond). 2024. PMID: 39239007 Free PMC article.
-
Efficacy and safety of catheter ablation with vein of Marshall ethanol infusion in patients with persistent AF and HFrEF.Biomed Rep. 2025 Jul 17;23(3):153. doi: 10.3892/br.2025.2031. eCollection 2025 Sep. Biomed Rep. 2025. PMID: 40746491 Free PMC article.
References
-
- Krijthe B.P., Kunst A., Benjamin E.J., Lip G.Y.H., Franco O.H., Hofman A., Witteman J.C.M., Stricker B.H., Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 2013;34:2746–2751. doi: 10.1093/eurheartj/eht280. - DOI - PMC - PubMed
-
- Duytschaever M., De Pooter J., Demolder A., El Haddad M., Phlips T., Strisciuglio T., Debonnaire P., Wolf M., Vandekerckhove Y., Knecht S., et al. Long-term impact of catheter ablation on arrhythmia burden in low-risk patients with paroxysmal atrial fibrillation: The CLOSE to CURE study. Heart Rhythm. 2020;17:535–543. doi: 10.1016/j.hrthm.2019.11.004. - DOI - PubMed
-
- O’Neill L., Almorad A., El Haddad M., Wielandts J.-Y., Gillis K., Hilfiker G., de Becker B., Lycke M., Tavernier R., le Polain de Waroux J.-B., et al. Impact of Catheter Ablation on Arrhythmia Burden in Patients With Shock-Resistant Persistent Atrial Fibrillation. JACC Clin. Electrophysiol. 2023;9:2071–2081. doi: 10.1016/j.jacep.2023.06.004. - DOI - PubMed
-
- Chew D.S., Li Z., Steinberg B.A., O’Brien E.C., Pritchard J., Bunch T.J., Mark D.B., Patel M.R., Nabutovsky Y., Greiner M.A., et al. Arrhythmic Burden and the Risk of Cardiovascular Outcomes in Patients With Paroxysmal Atrial Fibrillation and Cardiac Implanted Electronic Devices. Circ. Arrhythmia Electrophysiol. 2022;15:e010304. doi: 10.1161/CIRCEP.121.010304. - DOI - PubMed
-
- Glotzer T.V., Daoud E.G., Wyse D.G., Singer D.E., Ezekowitz M.D., Hilker C., Miller C., Qi D., Ziegler P.D. The Relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk the trends study. Circ. Arrhythmia Electrophysiol. 2009;2:474–480. doi: 10.1161/CIRCEP.109.849638. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources